FWBI stock gains as IND amendment for adrulipase is under FDA review (NASDAQ:FWBI)

FDA headquarters in Washington DC.


Nano-cap biotech First Wave BioPharma (NASDAQ:FWBI) announced that its Investigational New Drug (IND) amendment for adrulipase targeted at the digestive disorder exocrine pancreatic insufficiency is currently under FDA review.

In November, the company announced the submission of an IND

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!